This was accompanied by significant enhancement of DC maturation in tumor-draining lymph nodes (TDLNs), as the proportion of CD80+CD86+ mature DCs increased from 10.0% in the control group to 17.2% in the LipoNCs@pVector group and further to 41.3% in the LipoNCs@pGSDMB group (Fig. 5G and fig. The gene discussed is CD80; the disease is neoplasm.